mary treatment of choice of these diseases is to prevent thrombin generation using heparin and warfarin. Heparin is conventionally used as an anticoagulant; however, it has some limitations such as bleeding, unpredictable inter-patient and intra-patient pharmacokinetic/pharmacodynamic effects, heparin-induced thrombocytopenia (HIT), and with prolonged administration, osteoporosis. New anticoagulant drugs such as argatroban and recombinant hirudin have been approved for prophylaxis of thromboembolic complications in heparin-compromised patients. Other antithrombin and anti-Xa agents are in various phases of clinical development. Because the clinical effects of these agents vary and the dosing is not optimized, there is a need to monitor these drugs with a suitable method. Initially global tests such as the PT and the activated partial thromboplastin time (aPTT) have been used. PT is commonly used to monitor these agents, and attempts to use INR have been made. However, false elevations of INR were observed with some agents. Except for pentasaccharide, these agents have been shown to prolong the PT/INR values. The aim of this study is to compare four different PT reagents and to study the variations in INR values. It is of crucial importance to understand the interference of these novel anti-Xa and anti-IIa agents in the measurement of the INR values and to use safe monitoring strategies to avert bleeding or thrombotic complications.
MATERIALS AND METHODS

Materials
PT reagents:
Four different PT reagents were used in this study: a. 
Methods
In vitro study
Blood bank plasma frozen and stored at -70°C was thawed. Antithrombin drugs (hirudin, PEGhirudin, argatroban, and efegatran) and pentasaccharide were supplemented to the plasma in the concentration range of 0 to 1 µg/mL. Similarly, direct anti-Xa drugs (JTV-803 and DX 9065a) were supplemented to the plasma in the concentration range of 0 to 25 µg/mL. PT assays were performed using four different PT reagents and INR values were calculated.
In vivo study
Four healthy volunteers received JTV-803 at a dose of 0.15 mg/kg/hour infusion for 24 hours and blood samples were obtained before treatment, at the 4th hour of infusion, end of infusion, and 6 hours after the end of infusion. PT assays were performed with four different PT reagents on the plasma.
RESULTS
Antithrombin drugs, hirudin, argatroban, and PEG-hirudin, were supplemented in normal human plasma and serial dilutions were made in the concentration range of 0 to 1 µg/mL. A concentration-dependent response was observed on the PT assay with all the drugs studied. The decreasing order of potency of these drugs was ar-gatroban> hirudin> PEG-hirudin = efegatran. The calibration curves of different antithrombin drugs using thromboplastin C plus as a reagent for PT measurement is shown in Fig. 1 . The INR values were determined in the antithrombin supplemented plasma samples. The INR values were increased in a similar fashion corresponding to the PT values for all the antithrombin drugs. The effect of different antithrombin drugs on PT-INR measurements using thromboplastin C plus as a reagent for PT-INR measurement is shown in Fig. 2 .
Direct anti-Xa drugs, DX-9065a and JTV-803, were supplemented in normal human plasma and serial dilutions were made in the concentration range of 0 to 25 µg/mL. A concentration-dependent response was observed on the PT assay with both of these drugs studied. DX-9065a was found to be more potent than JTV-803. The calibration curves of different anti-Xa drugs using thromboplastin C plus as a reagent for PT measurement is shown in Fig. 3 . The INR values were determined in anti-Xa supplemented plasma samples. The INR values were increased in a similar fashion corresponding to the PT values for all the anti-Xa drugs.
The effect of different anti-Xa drugs on PT-INR measurements using thromboplastin C plus as a reagent for PT-INR measurement is shown in Fig.  4 . Indirect factor Xa inhibitor, pentasaccharide was supplemented in normal human plasma and serial dilutions were made in the concentration range of 0 to 25 µg/mL. There was no response observed on the PT assay with four different PT reagents. This is shown in Fig. 5 . Pentasaccharide did not affect PT-INR values using PT reagents mentioned subsequently. It is shown in Fig. 6 . The laboratory analysis of volunteers administered JTV-803 at a dose of 0.15 mg/kg/hour infusion for 24 hours, an anti-Xa agent on PT measurements using different PT reagents is given in Fig. 7 . The PT levels were found to be increased with different PT reagents at 4 hours after the start of infusion to the end of infusion and reached a peak at the end of infusion. At 6 hours after the end of infusion time, the PT levels were still higher in the increasing order of innovin>simplastin>thromboplastin C>recombiplastin. This is given in Fig. 7 .
The laboratory analysis of volunteers given JTV-803 at a dose of 0.15 mg/kg/hour infusion for 24 hours, an anti-Xa agent on PT-INR measurements using different PT reagents is shown in Fig. 8 . The INR levels were found to increase with different PT reagents at 4 hours after the start of infusion to the end of infusion and reached the peak at the end of infusion. At 6 hours after the end of infusion time, the PT levels were still higher in the increasing order of in-novin>recombiplastin>thromboplastin C>simplastin. This is given in Fig. 8 . 
FIG. 7.
This graph shows the laboratory analysis of volunteers administered with JTV-803 at a dose of 0.15 mg/kg/hour infusion for 24 hours, an anti-Xa inhibitor on PT measurements using different PT reagents. The PT levels were found to increase with different PT reagents at 4 hours post start of infusion the end of infusion and reached the peak at the end of infusion. At 6 hours post end of infusion time, the PT levels were still higher in the increasing order of innovin>simplastin> thromboplastin C>recombiplastin.
FIG. 6. This graph shows the effect of pentasaccharide on PT-INR measurements using PT reagents for PT measurement.
The effect of different anti-Xa drugs on INR measurements using different prothrombin reagents was studied. The INR measurements at the IC 50 concentrations according to anti-Xa activities of pentasaccharide, DX-9065a, and JTV-803 were 0.16, 6.20, and 12.01 µg/mL, respectively. In these IC 50 values, corresponding PT results are given in Table 1 . The effect of different anti-IIa drugs on INR measurements using different prothrombin reagents was studied. The INR measurements at the IC 50 concentrations according to anti-IIa activities of argatroban, PEGhirudin, and hirudin were more than 1 µg/mL and the IC 50 value for efegatran was 0.5 µg/mL. In these IC 50 values, corresponding PT results are given in Table 2 .
DISCUSSION
One of the novel potential problems with the INR measurement is their alteration caused by different anti-Xa and anti-IIa drugs. With the ad-vent of anti-IIa drugs such as argatroban, recombinant hirudin, PEG-hirudin, and efegatran, and anti-Xa drugs such as pentasaccharide, DX-9065a, and JTV-803, it is important to monitor these drugs with an optimum assay. Drugs such as argatroban, r-hirudin, and pentasaccharide have been appoved by the US Food and Drug Administration for the prophylaxis of thromboembolic complications in various indications. These drugs, with the exception of the pentasaccharide, increase the PT/INR values, posing a problem in the proper monitoring of these drugs and their dosage adjustments. Earlier reports have indicated problems in the interpretation of the INR values in individuals receiving warfarin concomitantly with argatroban (9) .
Direct thrombin inhibitors such as argatroban and recombinant hirudin are increasingly being used in the management of various disorders. These drugs are known to effectively inhibit the clot bound thrombin (10) . Similarly, the direct acting anti-Xa drugs are known to inhibit clotbound factor Xa. The aPTT assay is generally used to monitor direct thrombin inhibitors and a dose-dependent increase is also observed in the PT-INR values (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . Potential problems exist in the monitoring of warfarin, especially during the induction period, in patients on intravenous anticoagulation with a direct thrombin inhibitor who require long-term anticoagulation with warfarin. Because INR is used in the monitoring of the dosage of warfarin, concomitant use of direct thrombin inhibitor would pose a problem and other reliable means of monitoring warfarin therapy becomes essential. A similar problem arises when a patient on direct thrombin inhibitor during hospitalization is to be discharged on longterm oral anticoagulation with warfarin. Hence, any situation in which there is a concomitant use of direct thrombin inhibitor or direct anti-Xa inhibitor with warfarin, such problems in monitoring of warfarin will exist.
One such method developed in our laboratory and previously reported is based on factor Xa values as a means to assess the extent of oral anticoagulation in patients receiving antithrombin drugs (21) . Oral anticoagulants influence coagulation factors II, VII, IX, and X. Factor X can be measured with both clot-based and amidolyticbased method. This modified amidolytic method determines the decrease in the concentrations of functional factor X in patients administered warfarin and antithrombin drugs. Thus, oral anticoagulants such as warfarin can be monitored in the presence of a thrombin inhibitor by using amidolytic factor Xa assay.
This study demonstrates the influence of direct thrombin and direct factor Xa inhibitors on INR measurements. Furthermore, different PT reagents give different INR values under the influence of these drugs. Other potentially reliable means of monitoring assays are essential to avert bleeding in thrombotic complications. Different intravenous and oral anti-Xa and anti-IIa drugs are in various phases of clinical development. Oral thrombin inhibitors such as ximelagatran are not inferior to warfarin in clinical trials. Approval of ximelagatran may totally eliminate the use of warfarin and monitoring tests, such as PT/INR.
In the in vivo study where factor X a inhibitor JTV-803 was administered as an infusion at a dose of 1 µg/kg/hour, the PT results with thromboplastin C and recombiplastin provided increased clotting times and the calculated INR was markedly higher. In this scenario where patients are given factor Xa inhibitor and warfarin together, monitoring of warfarin poses a major problem again. Because warfarin inhibits vitamin K-dependent coagulation factors, II, VII, IX and X, direct measurement of coagulation factors II, VII, and IX may be of value in predicting the extent of anticoagulation with oral anticoagulants. Factors II and IX can determined only in clotbased assays. However, factor II or thrombin can be measured with both clot-based and amidolytic methods. A modified anti-factor IIa amidolytic method to determine the inhibition of functional factor II concentrations in patients who are given warfarin and concomitant factor Xa inhibitors such as JTV-803, DX9065a, and pentasaccharide has been recently studied (22) .
